Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Most Compelling Innovation Developments Somewhat recently - 2Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
- 3She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present?
- 4Tyler Childers' 'Snipe Hunt' 2026 Tour: How to get tickets, presale times, prices and more
- 5Amazon sued over 'punitive' handling of employee absences
- 10 Delectable Specialty Mixed drinks
- Expert advice for new stargazers: How to begin your amateur astronomy journey
- Instructions to Augment the Presentation of Your Kona SUV
- The Most Paramount Crossroads in Olympic History
- 3 back-to-back storms forecast to bring snow and surges of cold air across the Midwest to the Northeast
- Instructions to Upgrade the Security Elements of Your Kona SUV
- Blue Origin's next space tourism flight will break new ground for people with disabilities
- Electric Vehicles for Eco-Accommodating Driving
- Step by step instructions to Prepare with Senior Protection for Inward feeling of harmony.
